In hospital-acquired pneumonia with risk for MRSA and Pseudomonas, which empiric therapy is most appropriate?

Prepare for the PANCE Pulmonology Exam. Use flashcards and multiple choice questions with helpful explanations to boost your knowledge and confidence. Get exam ready!

Multiple Choice

In hospital-acquired pneumonia with risk for MRSA and Pseudomonas, which empiric therapy is most appropriate?

In hospital-acquired pneumonia with a risk for MRSA and Pseudomonas, you need broad initial coverage that targets both organisms because missing either can lead to worse outcomes. An antipseudomonal beta-lactam provides robust protection against Pseudomonas, while adding MRSA coverage with vancomycin or linezolid ensures MRSA is treated from the start. Relying on a single agent that only covers one of the bugs risks treatment failure if the other pathogen is present. A macrolide alone wouldn’t reliably cover either MRSA or Pseudomonas in this context. After culture results return, you can de-escalate to the narrowest effective regimen.

In hospital-acquired pneumonia with a risk for MRSA and Pseudomonas, you need broad initial coverage that targets both organisms because missing either can lead to worse outcomes. An antipseudomonal beta-lactam provides robust protection against Pseudomonas, while adding MRSA coverage with vancomycin or linezolid ensures MRSA is treated from the start. Relying on a single agent that only covers one of the bugs risks treatment failure if the other pathogen is present. A macrolide alone wouldn’t reliably cover either MRSA or Pseudomonas in this context. After culture results return, you can de-escalate to the narrowest effective regimen.

More practice questions